This post was originally published on this site
An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, interim data showed last week.
“We will be considering whether to start a rolling review for this compound in the next days. And of course, the idea is to understand if the data supports such (a) rolling review,” Marco Cavaleri, the EMA’s head of vaccine strategy, told reporters, when asked about Merck’s drug.
